Fundamental Analysis of KALVISTA PHARMACEUTICALS INC(NASDAQ:KALV) stock

Fundamental Rating

Overall KALV gets a fundamental rating of 2 out of 10. We evaluated KALV against 588 industry peers in the Biotechnology industry. KALV has a great financial health rating, but its profitability evaluates not so good. KALV does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year KALV has reported negative net income.

KALV had a negative operating cash flow in the past year.

In the past 5 years KALV always reported negative net income.

KALV had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

KALV has a Return On Assets of -95.03%. This is in the lower half of the industry: KALV underperforms 75.68% of its industry peers.

KALV's Return On Equity of -122.27% is in line compared to the rest of the industry. KALV outperforms 40.58% of its industry peers.

		Industry Rank	Sector Rank
ROA	-95.03%
ROE	-122.27%
ROIC	N/A

ROA(3y)-36.03%

ROA(5y)-31.44%

ROE(3y)-40.06%

ROE(5y)-35.29%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KALV so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

KALV has more shares outstanding than it did 1 year ago.

The number of shares outstanding for KALV has been increased compared to 5 years ago.

There is no outstanding debt for KALV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 2.55 indicates that KALV is not a great score, but indicates only limited risk for bankruptcy at the moment.

The Altman-Z score of KALV (2.55) is better than 74.49% of its industry peers.

KALV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	2.55

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 5.44 indicates that KALV has no problem at all paying its short term obligations.

KALV has a Current ratio of 5.44. This is comparable to the rest of the industry: KALV outperforms 57.88% of its industry peers.

A Quick Ratio of 5.44 indicates that KALV has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 5.44, KALV is in line with its industry, outperforming 58.73% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	5.44
Quick Ratio	5.44

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

KALV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.76%, which is quite good.

EPS 1Y (TTM)11.76%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-12%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, KALV will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.84% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y7.96%

EPS Next 2Y12.16%

EPS Next 3Y22.64%

EPS Next 5Y17.84%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

KALV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year KALV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

KALV's earnings are expected to grow with 22.64% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y12.16%

EPS Next 3Y22.64%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for KALV!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

KALVISTA PHARMACEUTICALS INC

NASDAQ:KALV (4/26/2024, 7:00:02 PM)

After market: 10.78 0 (0%)

10.78

+0.29 (+2.76%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap454.81M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-95.03%
ROE	-122.27%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	5.44
Quick Ratio	5.44
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)11.76%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y7.96%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

KALVISTA PHARMACEUTICALS INC (KALV)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens